The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
You caught me red handed, that's me, manipulator in chief !
One problem though, I've never said one negative word on here about the science or the pipeline and I've been holding and not sold a bean for 12 months !
Your problem, which is a very big one, is that you don't like the truth.
@fullfathomfive
I realised what you name stands for:
“Depth charges away!”
I reckon you are one of the chief manipulators... So what price have you set TILS up for next week, during your last golf session?
This company is turning itself into a laughing stock, absolute amateurs !
It's little wonder we are now struggling to break £1, the market lost confidence many months ago
Hi again,
No problem - this whole saga has become so complicated it's getting ridiculous.
Cheers
RokerP
RokerP, you’re right. Ignore my last message.
Hi Trade Phoenix,
Sorry, don't think so.
The 20-F facilitates the distribution of Accustem shares to US TILS holders. It isn't a filing for listing. Once the distribution is done then they can proceed with a listing . As they said in yesterday's RNS, they "intend" to file a listing application . If they had done it already they wouldn't say they were intending to do it.
"NEW YORK and LONDON - 30 March 2021 - Tiziana Life Sciences. (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, is pleased to confirm that, in order to finalise the distribution of shares in Accustem Sciences Limited ("Accustem") to the holders of Tiziana shares in the US via its ADS program, it has recently filed a Form 20-F with the Securities Exchange Commission in the USA (the "SEC"). The Form 20-F (which gives full information about the business of Accustem), can be found at https://sec.report/CIK/0001850767.
Once the SEC has approved the Form 20-F (or it becomes effective), the final aspect of the distribution will be complete and Accustem will be an entirely separate entity and will move forward with plans to secure its own listing."
RokerP
They did:
https://www.lse.co.uk/rns/TILS/accustem-update-x7enkf0upxj8czf.html
When they issue and RNS saying that they have actually filed a listing application with NASDAQ then I'd expect things to really move forward. As per yesterday's RNS they are still just "intending" to:
NEW YORK and LONDON, April 13, 2021 - Tiziana Life Sciences plc (NASDAQ: TLSA; LSE: TILS), today announced that its former subsidiary, Accustem Sciences Limited ("Accustem"), intends to file a listing application with the Nasdaq Stock Market shortly after completion of the distribution of shares in Accustem to Tiziana Life Sciences plc shareholders.
This is from yesterday's RNS.
"The board of directors of Accustem has resolved that the Nasdaq listing venue is more appropriate to the nature of Accustem's business."
When they say "more appropriate" they must mean more appropriate than the LSE, which was the initial choice.
On timing, they only ever used words like "expect" or "intend" about the listing - they could never actually make a binding commitment to timing, only give an indication. Listing a pre-revenue companies with US and UK shareholders was never going to be easy - they should never have created timing expectations.
I always thought that the likelihood was that they were just carving Accustem out to make it easier to value and sell separately - the listing was always likely to take a lot of work.